search icon
mrsn-img

Mersana Therapeutics Inc, Common Stock

MRSN

NSQ

$0.349

-$0.02

(-5.47%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$48.61M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
2.24M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.30
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.26 L
$2.83 H
$0.349

About Mersana Therapeutics Inc, Common Stock

Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops antibody-drug conjugates (ADC) for cancer patients with unmet needs. The company develops Emi-Le (XMT-1660), a B7-H4-targeting Dolasynthen ADC candidate, which is in Phase 1 clinical trial; and XMT-2056, an Immunosynthen ADC targeting a novel human epidermal growth factor receptor 2 that is in Phase 1 clinical trial. Its preclinical products portfolio includes XMT-2068 and XMT-2175. It has strategic research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana Biosciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameMRSNSectorS&P500
1-Week Return-10.51%0.71%0.79%
1-Month Return-5.52%-5.6%6.04%
3-Month Return-33.32%-11.72%-1.11%
6-Month Return-84.69%-10.81%-2.39%
1-Year Return-85.15%-7.12%11.69%
3-Year Return-89.55%-0.57%42.29%
5-Year Return-98.46%27.64%93.12%
10-Year Return-97.51%75.45%179.21%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue828.00K43.00K26.58M36.85M40.50M[{"date":"2020-12-31","value":2.04,"profit":true},{"date":"2021-12-31","value":0.11,"profit":true},{"date":"2022-12-31","value":65.64,"profit":true},{"date":"2023-12-31","value":91.01,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Cost of Revenue67.04M132.01M927.00K148.27M1.63M[{"date":"2020-12-31","value":45.21,"profit":true},{"date":"2021-12-31","value":89.04,"profit":true},{"date":"2022-12-31","value":0.63,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":1.1,"profit":true}]
Gross Profit(66.21M)(131.97M)25.65M(111.41M)40.50M[{"date":"2020-12-31","value":-163.49,"profit":false},{"date":"2021-12-31","value":-325.88,"profit":false},{"date":"2022-12-31","value":63.35,"profit":true},{"date":"2023-12-31","value":-275.12,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
Gross Margin(7996.14%)(306906.98%)96.51%(302.30%)100.00%[{"date":"2020-12-31","value":-7996.14,"profit":false},{"date":"2021-12-31","value":-306906.98,"profit":false},{"date":"2022-12-31","value":96.51,"profit":true},{"date":"2023-12-31","value":-302.3,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
Operating Expenses88.94M168.90M230.35M36.85M113.83M[{"date":"2020-12-31","value":38.61,"profit":true},{"date":"2021-12-31","value":73.32,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":16,"profit":true},{"date":"2024-12-31","value":49.42,"profit":true}]
Operating Income(87.69M)(169.71M)(204.69M)(170.96M)(73.34M)[{"date":"2020-12-31","value":-8768600000,"profit":false},{"date":"2021-12-31","value":-16971300000,"profit":false},{"date":"2022-12-31","value":-20469400000,"profit":false},{"date":"2023-12-31","value":-17095700000,"profit":false},{"date":"2024-12-31","value":-7333600000,"profit":false}]
Total Non-Operating Income/Expense130.00K(2.40M)(890.00K)6.31M9.12M[{"date":"2020-12-31","value":1.42,"profit":true},{"date":"2021-12-31","value":-26.35,"profit":false},{"date":"2022-12-31","value":-9.75,"profit":false},{"date":"2023-12-31","value":69.11,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Pre-Tax Income(88.05M)(170.06M)(204.21M)(171.67M)(68.77M)[{"date":"2020-12-31","value":-8804500000,"profit":false},{"date":"2021-12-31","value":-17006000000,"profit":false},{"date":"2022-12-31","value":-20421200000,"profit":false},{"date":"2023-12-31","value":-17167000000,"profit":false},{"date":"2024-12-31","value":-6877400000,"profit":false}]
Income Taxes359.00K(855.00K)3.33M1.35M418.00K[{"date":"2020-12-31","value":10.79,"profit":true},{"date":"2021-12-31","value":-25.69,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":40.54,"profit":true},{"date":"2024-12-31","value":12.56,"profit":true}]
Income After Taxes(88.40M)(169.21M)(207.54M)(173.02M)(69.19M)[{"date":"2020-12-31","value":-8840400000,"profit":false},{"date":"2021-12-31","value":-16920500000,"profit":false},{"date":"2022-12-31","value":-20754000000,"profit":false},{"date":"2023-12-31","value":-17301910500,"profit":false},{"date":"2024-12-31","value":-6919200000,"profit":false}]
Income From Continuous Operations(88.05M)(170.06M)(204.21M)(197.05M)(69.19M)[{"date":"2020-12-31","value":-8804500000,"profit":false},{"date":"2021-12-31","value":-17006000000,"profit":false},{"date":"2022-12-31","value":-20421200000,"profit":false},{"date":"2023-12-31","value":-19705000000,"profit":false},{"date":"2024-12-31","value":-6919200000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(88.40M)(169.21M)(207.54M)(171.67M)(69.19M)[{"date":"2020-12-31","value":-8840400000,"profit":false},{"date":"2021-12-31","value":-16920500000,"profit":false},{"date":"2022-12-31","value":-20754000000,"profit":false},{"date":"2023-12-31","value":-17167000000,"profit":false},{"date":"2024-12-31","value":-6919200000,"profit":false}]
EPS (Diluted)(1.43)(2.40)(2.19)(1.42)(0.56)[{"date":"2020-12-31","value":-143,"profit":false},{"date":"2021-12-31","value":-240,"profit":false},{"date":"2022-12-31","value":-219,"profit":false},{"date":"2023-12-31","value":-142,"profit":false},{"date":"2024-12-31","value":-56,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

MRSN
Cash Ratio 1.76
Current Ratio 1.83

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

MRSN
ROA (LTM) -30.90%
ROE (LTM) -505.14%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

MRSN
Debt Ratio Lower is generally better. Negative is bad. 1.27
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. -0.27

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

MRSN
Trailing PE NM
Forward PE NM
P/S (TTM) 1.34
P/B 32.03
Price/FCF NM
EV/R 4.66
EV/Ebitda NM
PEG NM

FAQs

What is Mersana Therapeutics Inc share price today?

Mersana Therapeutics Inc (MRSN) share price today is $0.349

Can Indians buy Mersana Therapeutics Inc shares?

Yes, Indians can buy shares of Mersana Therapeutics Inc (MRSN) on Vested. To buy Mersana Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in MRSN stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Mersana Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Mersana Therapeutics Inc (MRSN) via the Vested app. You can start investing in Mersana Therapeutics Inc (MRSN) with a minimum investment of $1.

How to invest in Mersana Therapeutics Inc shares from India?

You can invest in shares of Mersana Therapeutics Inc (MRSN) via Vested in three simple steps:

  • Click on Sign Up or Invest in MRSN stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Mersana Therapeutics Inc shares
What is Mersana Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Mersana Therapeutics Inc (MRSN) is $2.83. The 52-week low price of Mersana Therapeutics Inc (MRSN) is $0.26.

What is Mersana Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Mersana Therapeutics Inc (MRSN) is 32.03

What is the Market Cap of Mersana Therapeutics Inc?

The market capitalization of Mersana Therapeutics Inc (MRSN) is $48.61M

What is Mersana Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of Mersana Therapeutics Inc is MRSN

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top